These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 29497803)

  • 1. Prospective observational study of
    Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized
    Del Prete M; Buteau FA; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
    Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
    J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of peptide receptor radionuclide therapy with
    Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y
    Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
    Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
    Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized
    Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
    Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry and pharmacokinetics of [
    Schürrle SB; Eberlein U; Ansquer C; Beauregard JM; Durand-Gasselin L; Grønbæk H; Haug A; Hicks RJ; Lenzo NP; Navalkissoor S; Nicolas GP; Pais B; Volteau M; Wild D; McEwan A; Lassmann M
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2428-2441. PubMed ID: 38528164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.
    Fröss-Baron K; Garske-Roman U; Welin S; Granberg D; Eriksson B; Khan T; Sandström M; Sundin A
    Neuroendocrinology; 2021; 111(4):330-343. PubMed ID: 32097917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.
    Swärd C; Bernhardt P; Ahlman H; Wängberg B; Forssell-Aronsson E; Larsson M; Svensson J; Rossi-Norrlund R; Kölby L
    World J Surg; 2010 Jun; 34(6):1368-72. PubMed ID: 20066413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
    Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
    J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
    Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
    Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.
    Bergsma H; Konijnenberg MW; van der Zwan WA; Kam BL; Teunissen JJ; Kooij PP; Mauff KA; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1802-11. PubMed ID: 27160225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.